Autnami

Autnami combines Metformin Hydrochloride and Linagliptin for oral use, aiding blood sugar management. This dual-action medication supports metabolic health and is manufactured by Sandoz Pharmaceuticals D.D.

Autnami is primarily used to manage blood sugar levels in adults with type 2 diabetes. It combines Metformin Hydrochloride, which helps reduce glucose production in the liver, and Linagliptin, which works to increase insulin production. This combination is often prescribed to improve glycemic control when diet and exercise alone are not sufficient. Autnami is not intended for type 1 diabetes or diabetic ketoacidosis.

Common effects of Autnami may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when first starting the medication. Some users may also experience headaches or upper respiratory infections. These effects are generally mild and tend to diminish over time as the body adjusts to the medication.

Autnami should be used with caution in individuals with kidney or liver impairment. It is important to monitor blood sugar levels regularly and consult a healthcare provider before starting or adjusting the dosage. Autnami should not be taken without medical supervision, especially in pregnant or breastfeeding women.

Autnami may interact with certain medications, including other diabetes drugs, antibiotics, and medications that affect kidney function. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be limited, as it can affect blood sugar levels and increase the risk of side effects.